the aid library

LIST OPTIONS

Filter

5540

Assessing health systems in Guinea for prevention and control of priority zoonotic diseases: A One Health approach

Standleya C. J., Carlinb E. P., Sorrella E. M. et al. Elsevier (2019) CC

To guide One Health capacity building efforts in the Republic of Guinea in the wake of the 2014–2016 Ebola virus disease (EVD) outbreak, we sought to identify and assess the existing systems and structures for zoonotic disease detection and control. We partnered with the government ministries resp... more

External Link

Ethiopia - Multi-Sectorial Cholera Elimination Plan 2022 - 2028

Government of Ethiopia (2023) C2

The Ethiopia Multi-Sectorial Cholera Elimination Plan (2022-2028) outlines a national strategy to eliminate cholera in Ethiopia by 2028. The plan follows the Global Roadmap to End Cholera by 2030 and is based on six key pillars: Leadership & Coordination, Water, Sanitation & Hygiene (WASH), Surveill... more

Download (124)

View PDF (144)

Guidelines for Addressing Disease Risks in Wildlife Trade

World Organisation for Animal Health WOAH (2024) CC

For thousands of years, humans have been using wildlife for commercial and subsistence purposes. Wildlife trade takes place at local, national and international levels, with different forms of wildlife, such as live animals, partly processed products and finished products. Wildlife is a vital source... more

Download (333)

View PDF (292)

Guidance to facilitate monitoring and evaluation for antimicrobial resistance national action plans

Quadripartite: Food and Agriculture Organization of the United Nations FAO; UN Environment Programme UNEP; World Health Organization WHO; World Organisation for Animal Health WAHO (2023) CC

Antimicrobial resistance (AMR) is a global human, animal, plant and environment health threat that needs to be addressed by every country. The impacts of AMR are wide-ranging in terms of human health, animal health, food security and safety, environmental effects on ecosystems and biodiversity, and ...socioeconomic development. Just like the climate crisis, AMR poses a significant threat to the delivery of the 2030 Agenda for Sustainable Development. The response to the AMR crisis has been spearheaded through the global action plan on antimicrobial resistance (GAP-AMR), developed by the World Health Organization (WHO) in 2015, in close collaboration with the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (WOAH), and formally endorsed by the three organizations’ governing bodies and by the Political Declaration of the high-level meeting of the United Nations General Assembly on AMR in 2016. In 2022, the three organizations officially became the Quadripartite by welcoming the United Nations Environment Programme (UNEP) into the alliance “to accelerate coordination strategy on human, animal and ecosystem health”. The aim of the GAP-AMR is to ensure the continuity of successful treatment with effective and safe medicines. Its strategic objectives include: • improving the awareness and understanding of AMR; • strengthening the knowledge and evidence base through surveillance and research; • reducing the incidence of infection through effective sanitation, hygiene and infection prevention measures; optimizing the use of antimicrobial medicines in human and animal health; and • developing the economic case for sustainable investment that takes account of the needs of all countries and increasing investment in new medicines, diagnostic tools, vaccines and other interventions. With the adoption of the GAP-AMR, countries agreed to develop national action plans (NAPs) aligned with the GAP-AMR to mainstream AMR interventions nationally. Individually, the Quadripartite took action to advance AMR interventions in their respective sectors. FAO adopted a resolution on AMR recognizing that it poses an increasingly serious threat to public health and sustainable food production, and developed an AMR action plan to support the resolution’s implementation. For its part, WOAH developed a strategy on AMR aligned with the GAP-AMR, acknowledging the importance of a One Health approach to AMR. Similarly, more recently, UNEP’s governing body, the United Nations Environment Assembly, recognized that AMR is a current and increasing threat and a challenge to global health, food security and the sustainable development of all countries, and welcomed the GAP-AMR and the NAPs developed in accordance with its five overarching strategic objectives more

Download (235)

View PDF (180)

National Comprehensive Guidelines on HIV Testing Services

Kenya MInistry of Health, Community Development, Elderly and Children (2019) C1

These guidelines provide a framework for effective action to facilitate access to safe and ethical testing services for different population groups. The implementation of the a comprehensive approach, known as HIV Testing Services (HTS) is cardinal as an effective package of services that diminis... more

External Link

Surgical approaches to the urogenital manifestations of lymphatic filariasis

World Health Organization WHO (2019) C_WHO

During the 17 years since Surgical approaches to the urogenital manifestations of lymphatic filariasis was first published, there has been heightened awareness of the physical, economic and emotional burden of the genitourinary manifestations of filariasis. With the impetus to provide better guidanc... more

Download (345)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (125)

View PDF (189)

COVID-19 e segurança dos alimentos: Orientações para as autoridades competentes responsáveis pelos sistemas de controloda segurança dos alimentos

World Health Organization WHO (2020) C_WHO

A atual pandemia de COVID-19 constitui um desafio excepcional e sem precedentes para que as autoridades competentes, com responsabilidades nos sistemas nacionais de controlo da segurança dos alimentosa, possam continuar a desempenhar as suas funções e atividades ... more

Download (221)

View PDF (390)

WHO recommendations for international traffic related to the Ebola Virus Disease outbreak in the Democratic Republic of the Congo

World Health Organization WHO (2019) C_WHO

Download (388)

View PDF (808)

Listeriosis: Clinical recommendations for diagnosis and treatment

Dept. of Health, Republic of South Africa (2017) C1

Download (115)

View PDF (140)

Updated WHO recommendations for international traffic in relation to COVID-19 outbreak

World Health Organization WHO (2020) C_WHO

29 February 2020

Download (188)

View PDF (234)

Technical considerations for implementing a risk-based approach to international travel in the context of COVID-19

World Health Organization WHO (2021) C_WHO

Interim guidanceAnnex to: Policy considerations for implementing a risk-based approach to international travel in the context of COVID-19, 2 July 2021

Download (618)

View PDF (442)

Practical Epidemiology

Vaughan, P.; C. Victora and M. Chowdury. (2021) C1

Using Epidemiology to Support Primary Health Care. Updated version of the WHO handbook published in the early 1990's entitled: Manual of Epidemiology for District Health Management or those with an interest in applied epidemiology in primary health care and district health systems

Download (449)

View PDF (588)

'Idea to Reality': Strategy and Implementation Plan 2017-2021

Federal Ministry of Health - Nigeria Centre for Disease Control (2017) C2

Download (312)

View PDF (442)

Guia Provisório da OMS para a Doença do Vírus do Ébola Rastreio à Saída nos Aeroportos, Portos Marítimos e Fronteiras Terrestres

Organização Mundial da Saúde (2014) C_WHO

Download (1064)

View PDF (2040)

Eliminación de las desigualdades en salud cada mujer y cada infante cuentan

Federación Internacional de Sociedades de la Cruz Roja y Media Luna Roja (2011)

1. Salvar vidas, proteger los medios de sustento y apoyar la recuperación de desastres y crisis 2. Posibilitar una vida sana y segura 3. Promover la inclusión social y una cultura de no violencia y la paz

Download (2277)

View PDF (1227)

India's Healthcare System - Overview and Quality Improvements

Growth Analysis Studentplan (2013) CC

Download (1397)

View PDF (2363)

Immunization Essentials a practical Field Guide

USAID USAID (2004) CC

This guide provides a comprehensive overview of essential information related to immunization, including technical information about vaccines, a review of immunization program management best practices, guidance on the delivery of immunization services, monitoring and evaluation, disease surveillanc... more

Download (554)

View PDF (1073)

Fifth meeting of the Emergency Committee under the International Health Regulations (2005) regarding microcephaly, other neurological disorders and Zika virus

World Health Organization WHO (2016)

Download (362)

View PDF (825)

WHO recommendations for international travellers related to the Ebola Virus Disease outbreak in the Democratic Republic of the Congo

World Health Organization WHO (2018)